Comparison of the efficacy of aerosol inhalation between the ipratropium bromide and terbutaline on the patients with AECOPD.

To observe the clinical efficacy of aerosol inhalation of ipratropium bromide and terbutaline on the patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). A total of 136 COPD patients with acute exacerbation were divided into the ipratropium bromide group (n=69) and the terbutaline group (n=67). Patients in the ipratropium bromide group were required to take ipratropium bromide, while those in the terbutaline group took terbutaline for 3 days. Then, changes in symptoms, vital signs, blood-gas indicators and pulmonary functions were compared and analyzed between two groups. In ipratropium bromide group, patients with amelioration in vital signs and symptoms, especially for the symptom of coughing (P<0.01), were more than those in the terbutaline group, with statistically significant difference (P<0.05). In addition, following medication, analysis showed that the improvement in the blood-gas indicators and pulmonary functions in the ipratropium bromide was excellent in comparison with the terbutaline group, especially the improvement in the pulmonary ventilation function (P<0.01). Comparison over the incidence rates of adverse events in the ipratropium bromide group and terbutaline group showed an evident difference (P<0.05). For treatment of patients with acute exacerbation of COPD, aerosol inhalation of ipratropium bromide is a safe but effective method.